Adverse Events of Adjuvant Mitotane Treatment for Adrenocortical Carcinoma

Mitotane is the cornerstone of adjuvant adrenocortical cancer (ACC) treatment. However, its use is burdened with frequent adverse events. A retrospective analysis of adverse events was performed in 26 ACC patients adjuvantly treated with mitotane. Mitotane toxicity was present in all patients (100%)...

Full description

Saved in:
Bibliographic Details
Published in:Endocrine research 2024-09, p.1-7
Main Authors: Vodanović, Ivana Dora, Barač Nekić, Anja, Šambula, Lana, Zibar Tomšić, Karin, Dušek, Tina, Kaštelan, Darko
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mitotane is the cornerstone of adjuvant adrenocortical cancer (ACC) treatment. However, its use is burdened with frequent adverse events. A retrospective analysis of adverse events was performed in 26 ACC patients adjuvantly treated with mitotane. Mitotane toxicity was present in all patients (100%). Two (7.7%) patients developed 1-3 adverse events, 15 (57.7%) experienced 4-6 adverse events and 9 (34.6%) patients had more than 6 adverse events. Two (7.7%) patients discontinued mitotane due to adverse events. Careful monitoring and timely management are essential for ensuring mitotane treatment adherence and maximizing its benefits.
ISSN:0743-5800
1532-4206
1532-4206
DOI:10.1080/07435800.2024.2402311